← Back to headlines
Iovance Biotherapeutics Reports Strong Revenue Growth Driven by Amtagvi
Iovance Biotherapeutics (IOVA) reported a 61% annual revenue growth, primarily attributed to the success of its drug Amtagvi.
26 Feb, 19:27 — 26 Feb, 19:27
Sources
Showing 1 of 1 sources
